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Background: Recurrent adverse cardiovascular events (MACE) are a challenge for
interventional cardiology. In the PROSPECT study, 697 patients with acute coronary
syndromes underwent coronary angiography and intravascular ultrasound for lesion
characterization. We aimed at a biomarker based characterization of patients prone for
MACE and related the results to lesion characteristics.
Methods: We measured a large set of vascular and cardiovascular risk related biomarkers
including hsTnI, GDF-15, PLGF, sFLT-1, homocysteine, NGAL, hsCRP, LP(a), Cystatin
C, ApoA1, ApoB and beta-2-microglobulin in baseline, day 30 and day 180 blood
samples of the PROSPECT study and analysed the relation to outcome. Markers for
multivariate analysis were sFLT-1, Cystatin C and beta-2-microglobulin selected by p
0.1 in bivariate analysis. The biomarkers were tested using either commercially
available or prototype ARCHITECT(R) assays.Three years MACE (death from cardiac
causes, cardiac arrest, myocardial infarction, or rehospitalization due to unstable or
progressive angina) were related to a non-culprit lesion of the index event (NCMACE).
Results: Median [IQR] sFLT-1 levels were higher in patients without NCMACE 735.5
[334.2, 4024.4] versus 479.2 [244.9, 1362.0] pg/mL (p0.03); Cystatin C was slightly
higher in patients with NCMACE 0.77 [0.68, 0.90] versus 0.72 [0.64, 0.84]mg/L
(p0.07) and so was the beta-2-microglobulin 1.99 [1.61, 2.31] versus 1.79 [1.52, 2.12]
mg/L (p0.02). At 6 months sFLT-1 decreased and the difference disappeared 212.4
[183.7, 252.1] versus 220.4 [191.7, 248.8], while the latter markers increased slightly and
remained significant. Patients with any MACE in the follow up had higher values of
GDF-15 at baseline 893.0 [716.3, 1254.3] versus 799.9 [616.9, 1130.1] pg/mL (p0.02),
also higher Cystatin C and beta-2-microglobulin and lower HDL and ApoA1. In the
multivariate analysis only insulin dependent diabetes (IDDM; HR 3.43 [ 1.38, 8.58]) and
history of AP remained significant predictors of NCMACE.
Conclusions: Patients with non-culprit lesions MACE in the long-term follow up have
specific biomarker profiles. This may impact for the personalization of intensified
anti-thrombotic treatment in the future.
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Background: Efficacy of primary percutaneous coronary intervention (pPCI) for acute
myocardial infarction has been established by abundant evidences, however, impact of
restenosis after pPCI in cardiac function or long-term prognosis remains unclear.
Methods: We investigated 339 STEMI patients who had undergone pPCI with bare
metal stent between May 2004 and June 2009 followed by rest (acute phasewithin 2
weeks) /exercise stress (chronic phase3 months after onset) 99m-Tc-Tetrofosmin
scintigraphy (TcTF) and follow-up coronary angiography (CAG). According to the result
of follow-up CAG, they were divided into three groups (A: no in-stent restenosis (ISR),
n228; B: ISR without occlusion, n86; C: ISR with occlusion, n25). Those with
symptomatic stent thrombosis before F/U CAG were excluded. Perfusion defect score
(DS), left ventricular ejection fraction (LVEF) and myocardial ischemia were evaluated
by TcTF. Re-hospitalization due to congestive heart failure, new onset acute coronary
syndrome (ACS) (except due to restenosis) and cardiac death were investigated as clinical
events.
Results: In acute phase, there were no significant differences in perfusion DS and LVEF
among three groups. However, in chronic phase, group C showed significantly lower
LVEF, greater perfusion DS than other two groups. Furthermore, during follow-up period
(3-8 years) prevalence of heart failure requiring rehospitalization and new onset ACS was
significantly higher in group C.
(A) No
ISR
(B) ISR
without
occlusion
(C) ISR
with
occlusion A vs.
B
A vs.
C
B vs.
CN228 N86 N25
Perfusion DS (acute) 18.1 18.6 20.6 N.S. N.S. N.S.
EF (%) (acute) 45.8 47.7 44.8 N.S. N.S. N.S.
Perfusion DS(chronic) 15.8 17.0 21.8 N.S. 0.05 0.05
EF (%) (chronic) 54.4 52.8 47.6 N.S. 0.05 0.05
CHF hospitalization (%) 8.4 9.4 40.0 N.S.0.001 0.001
Total Events (%) 14.0 14.0 56.0 N.S.0.001 0.001
Conclusions: Silent occlusion after pPCI is associated with deteriorated cardiac function,
progression of chronic heart failure and rehospitalization. However, such observations
were not observed in non-occlusive ISR. Coronary artery patency, but not the grade of
stenosis is an important predictor of prognosis in STEMI treated by successful pPCI.
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Background: There are still debates regarding the benefits of adjunctive thrombectomy
devices in ST-elevation myocardial infarction (STEMI) patients undergoing primary
percutaneous coronary intervention (PCI). The objective of this study was to perform an
updated meta-analysis of published clinical trials conducted with adjunctive devices to
prevent distal embolization in the setting of primary PCI.
Methods: We searched MEDLINE, EMBASE, Cochrane databases for randomized,
case-control, and cohort studies on adjunctive devices to prevent distal embolization in
STEMI from January 2002 to May 2012.
Results: A total of 22 trials with 7,229 patients were included. The use of adjunctive
thrombectomy devices was associated with significantly higher incidence of postproce-
dural ST-segment resolution (odds ratio [OR] 2.04, 95% confidence interval [CI] 1.50 to
2.78, p0.001) and myocardial blush grade 3 (OR 2.26, 95% CI 1.34 to 3.81, p0.002).
There were no significant differences in the rates of final Thrombolysis in Myocardial
Infarction grade 3 flow (OR 1.19, 95% CI 0.88 to 1.62, p0.25) and incidence of distal
embolization (OR 0.61, 95% CI 0.37 to 1.02, p0.06). Thrombectomy devices were
associated with a significant reduction in MACE (OR 0.81, 95% CI 0.68 to 0.98, p0.03)
with no difference in mortality (OR 0.97, 95% CI 0.73 to 1.29, p0.81).
Conclusions: Use of adjunctive thrombectomy devices is associated with better myo-
cardial perfusion and trend toward lesser distal embolization after primary PCI without
significant improvement in mortality.
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Background: The impact of culprit vessel size on outcome in primary percutaneous
coronary intervention (PPCI) is not well studied. We aimed to analyse the incidence,
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